Candidate Biomarker of Response to Immunotherapy In Small Cell Lung Cancer
- 22 January 2025
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 26 (2) , 73-83
Abstract
Opinion Statement Small-cell lung cancer accounts for about 15% of lung cancers with an extremely poor prognosis. The incorporation of immunotherapy to platinum-based chemotherapy offers sustained overall survival benefits and become the standard for the first-line setting of extensive-stage small-cell lung cancer. However, only a limited number of patients derive prolonged benefits. Although novel immunomodulatory agents and combination strategies are currently under investigation, identifying patients who are likely to obtain clinical benefits from this therapeutic approach is urgently needed. The modest therapeutic response to immunotherapy can be explained by various mechanisms. Traditional biomarkers do not guide immunotherapeutic decision-making in small-cell lung cancer. Notably, recent progress in the understanding of the molecular typing of small-cell lung cancer based on multi-omics data might bring new sights. This review summarizes the potential biomarkers for small-cell lung cancer immunotherapy based on clinical trials and preclinical studies. Moreover, important constraints in identifying biomarkers for small-cell lung cancer treatment are discussed.Keywords
Funding Information
- Huzhou Science and Technology Project (2023GY15)
This publication has 67 references indexed in Scilit:
- Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapyClinical and Translational Oncology, 2024
- Advancing immunotherapy in small cell lung cancerCancer, 2023
- LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005)Annals of Oncology, 2022
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆Annals of Oncology, 2021
- Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumabCancer Immunology, Immunotherapy, 2021
- Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phaseCancer Immunology, Immunotherapy, 2020
- Blockade of myeloid-derived suppressor cell function by valproic acid enhanced anti-PD-L1 tumor immunotherapyBiochemical and Biophysical Research Communications, 2020
- An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in CancerCancer Cell, 2019
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung CancerCancer Cell, 2018
- Small cell lung cancer tumour cells induce regulatory T lymphocytes, and patient survival correlates negatively with FOXP3+ cells in tumour infiltrateInternational Journal of Cancer, 2012